Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Report Third Quarter 2019 Financial Results
SAN DIEGO , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2019 financial results on Wednesday, October 30, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
SAN DIEGO , Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of life in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN)
View HTML
Toggle Summary Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created position, Mr. Heerma will be responsible for leading Retrophin’s commercial organization and
View HTML
Toggle Summary Retrophin to Present at the 2019 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the 2019 Cantor Global Healthcare Conference in New York City on Thursday, October 3, 2019 at 5:20 p.m. ET .
View HTML
Toggle Summary Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
FORT Study did not achieve its primary or secondary endpoints Company to host conference call and webcast today at 8:30 a.m. ET SAN DIEGO , Aug. 22, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Phase 3 FORT Study evaluating the safety and efficacy of
View HTML
Toggle Summary Retrophin Reports Second Quarter 2019 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Commercial launch for THIOLA ® EC underway following FDA -approval for the treatment of cystinuria Second quarter revenues increased eight percent to $45 million SAN DIEGO , Aug.
View HTML
Toggle Summary Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
SAN DIEGO , July 31, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET .
View HTML
Toggle Summary Retrophin to Report Second Quarter 2019 Financial Results
SAN DIEGO , July 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
 Enteric-coated formulation offers flexible dosing options, including administration with or without food THIOLA EC expected to be available to patients next month SAN DIEGO , June 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S.
View HTML
Toggle Summary Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient
View HTML